Coronary Artery Calcium Score Modifies the Risk of Coronary Heart Disease Associated with Apolipoprotein B
Abstract Body (Do not enter title and authors here): Introduction Apolipoprotein B (ApoB) and coronary artery calcium score (CAC) are well-established risk factors for coronary heart disease (CHD). However, the interaction between these risk factors on CHD risk has not been well-studied. We investigated the association between ApoB levels and CAC with CHD risk. Methods We analyzed 4,649 participants from the Multiethnic Study of Atherosclerosis cohort (median follow-up 13.9 years) without baseline CHD or statin use. High ApoB was defined as ≥120 mg/dL. Participants were divided into 6 groups; group 1: CAC = 0 with normal ApoB, group 2: CAC = 0 with high ApoB, group 3: CAC 1-99 with normal ApoB, group 4: CAC 1-99 with high ApoB, group 5: CAC ≥100 with normal ApoB, group 6: CAC ≥100 with high ApoB. CHD was defined as myocardial infarction, resuscitated cardiac arrest, or CHD death. Survival analysis using Kaplan-Meier and multivariable Cox proportional hazard models were performed to assess the relationship between ApoB, CAC, and time to first CHD event. Results In an adjusted model, high ApoB, CAC (1-99), and CAC (≥100) were independently associated with CHD (HR: 1.48; 95% CI: 1.04, 2.11; HR: 2.54; 95% CI: 1.78, 3.64; and HR: 4.41; 95% CI: 3.08, 6.31, respectively). Compared to group 1 (CAC 0 with normal ApoB), CAC 0 and high ApoB (group 2) was not associated with increased risk of CHD (HR: 1.15; 95% CI: 0.59, 2.23). However, a statistically significant greater risk of CHD was observed in those with CAC 1-99 and normal ApoB (group 3) (HR: 2.12; 95% CI: 1.37, 3.28), CAC 1-99 and high ApoB (group 4) (HR: 4.12; 95% CI: 2.42, 7.00), CAC ≥100 and normal ApoB (group 5) (HR: 4.20; 95% CI: 2.78, 6.34), CAC ≥100 and high ApoB (group 6) (HR: 5.72; 95% CI: 3.40, 9.63). Conclusions In this analysis, ApoB and CAC are independently associated with CHD risk. Individuals with high ApoB and CAC ≥100 had the highest risk of CHD. In contrast, individuals with CAC = 0 and high ApoB had no significant increase in CHD risk compared to individuals with normal ApoB levels. These findings suggest that ApoB and CAC may be complementary tools for CHD risk stratification in the context of primary prevention.
Vergara, Carlos
( Mayo Clinic
, Jacksonville
, Florida
, United States
)
Krasner, Joshua
( University of Miami Miller School of Medicine, Holy Cross Hospital
, Fort Lauderdale
, Florida
, United States
)
Mark, Justin
( University of Miami Miller School of Medicine, Holy Cross Hospital
, Fort Lauderdale
, Florida
, United States
)
Lopez, Jose
( University of Miami Miller School of Medicine, JFK Hospital
, Atlantis
, Florida
, United States
)
Colombo, Rosario
( University of Miami Miller School of Medicine, Jackson Memorial Hospital
, Miami
, Florida
, United States
)
Yang, Eugene
( University of Washington
, Seattle
, Washington
, United States
)
Shapiro, Michael
( Wake Forest Univ School of Medicine
, Winston Salem
, North Carolina
, United States
)
Author Disclosures:
Carlos Vergara:DO NOT have relevant financial relationships
| Joshua Krasner:DO NOT have relevant financial relationships
| Justin Mark:DO NOT have relevant financial relationships
| Jose Lopez:No Answer
| Rosario Colombo:No Answer
| Eugene Yang:DO have relevant financial relationships
;
Advisor:Qure.ai:Past (completed)
; Advisor:Mineralys:Active (exists now)
; Other (please indicate in the box next to the company name):American College of Cardiology:Active (exists now)
; Advisor:Idorsia:Active (exists now)
; Advisor:Genentech:Past (completed)
; Advisor:SkyLabs:Active (exists now)
| Michael Shapiro:DO have relevant financial relationships
;
Consultant:Ionis:Past (completed)
; Consultant:Arrowhead:Past (completed)
; Consultant:Regeneron:Past (completed)
; Researcher:New Amsterdam:Active (exists now)
; Researcher:Merck:Active (exists now)
; Researcher:Novartis:Active (exists now)
; Researcher:Esperion:Active (exists now)
; Researcher:Cleerly:Active (exists now)
; Researcher:Amgen:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Consultant:Tourmaline:Active (exists now)
; Consultant:Merck:Active (exists now)
; Consultant:New Amsterdam:Past (completed)
; Consultant:Novartis:Active (exists now)